Brin’s non-profit investment vehicle, Catalyst4, set up using the proceeds of his 2021 sale of his Tesla stake, has committed to cover around $15 million of a $25 million funding round for psychedelic start-up Soneira. The biotech company is launching clinical trials looking at ibogaine, a shrub native to West Africa, as a treatment for traumatic brain injury (TBI).

Historically, ibogaine has been used as part of spiritual rituals by forest-dwelling tribes in Gabon due to its mind-altering effects. Recently, it has gained traction among western psychedelic advocates and mental health researchers. A Stanford University project funded by Brin’s charitable foundation found that ibogaine therapy improved mental health symptoms and cognitive function in 30 US military veterans with TBI.

Interest from Silicon Valley

Soneira, advised by Stanford psychiatrist Nolan Williams who worked on the study, is researching how ibogaine can be combined with heart medications to mitigate the risk of fatal cardiac arrhythmia associated with the plant. The company is also developing a synthetic version of the compound and plans to launch early-stage clinical trials using the funding.

Silicon Valley’s enthusiasm for psychedelics, both for personal use and as an investment, is growing. Catalyst4 was set up with cash from the $366 million windfall from Brin’s sale of his entire Tesla stake. Tesla founder Elon Musk has spoken publicly about his use of ketamine to treat depression, and billionaire tech investor Peter Thiel was one of the early backers of Atai Life Sciences, a biotech researching psychedelic-based mental health treatments that is also studying ibogaine to treat opioid-use disorder.

Venture capitalists have invested nearly $180 million in psychedelic biotechs so far this year, according to PitchBook data. Investment in the sector hit a record high in 2021, with $528 million raised.

Through the Sergey Brin Family Foundation, Brin has invested hundreds of millions of dollars into research into neurodegenerative and psychological conditions. Brin, the world’s seventh-richest person according to Forbes, discovered in 2004 that he possesses a genetic mutation that puts him at heightened risk of Parkinson’s disease.

Catalyst4, which had total assets of $430 million at the end of 2022, has a mandate to invest in breakthrough treatments for neurological disorders and technology to mitigate climate change. One Catalyst4 board member also works for Brin’s family office, Bayshore Global Management, which with at least $100 billion of assets is one of the biggest family offices globally.

Around half-a-dozen other parties have also held discussions about investing in Soneira, including Helena Special Investments, the impact investor behind Lykos Therapeutics, which is awaiting an approval decision by regulators for MDMA as a treatment for post-traumatic stress disorder, and digital health start-up investor LifeForce Capital. Soneira’s funding round is set to close after summer.

The post Google co-founder fuels psychedelic biotech’s leap into mental health treatment appeared first on AIBC.

Breakthrough in primary healthcare

With the increasing strain on the National Health Service (NHS), the deployment of AI stethoscopes in primary care emerges as a crucial tool to alleviate the burden and save lives.

The Eko AI stethoscope, designed to detect heart diseases within seconds, aims to revolutionize diagnostics and significantly reduce waiting times, offering hope for patients in need.

Closing the detection gap

The Golborne Medical Centre, located in one of the UK’s most deprived areas, has unveiled a revolutionary tool set to transform the diagnosis of heart disease.

The introduction of AI stethoscopes, a first in the UK’s primary care sector, holds the promise of not only saving lives but also easing the immense pressure faced by the NHS.

Traditionally, stethoscopes have remained unchanged for over two centuries. However, the AI-powered stethoscope, developed by Mayo Clinic spin-off Eko, is poised to disrupt the conventional approach. Equipped with artificial intelligence, this innovative tool offers instant detection of heart diseases, marking a significant leap forward in diagnostic capabilities.

The Golborne practice, serving a diverse population, is among the 200 GP surgeries in north-west London and Wales to receive the AI stethoscope. This move is especially crucial for areas with a higher risk of heart disease-related fatalities, particularly among non-white minority ethnic groups.

Licensed by medical regulators

Medical regulators have granted the necessary licences for the use of the AI stethoscope by general physicians. What sets this tool apart is its ability to prescribe life-saving medication without the need for specialist reviews, making it a reliable solution in critical situations.

As the NHS faces one of its most challenging winters, the timing of this technological advancement couldn’t be more critical. With nearly 7.7 million non-emergency appointments awaiting attention, the AI stethoscope emerges as a potential game-changer. Its rapid results, cost-effective deployment, and ability to prioritize patients on waiting lists offer a glimmer of hope in the face of overwhelming demand.

Patient waiting list will be reduced

NHS cardiologist Mihir Kelshiker, overseeing the tool’s deployment, highlighted the potential to save lives and unlock substantial savings for the health system. With an estimated 300,000 patients on diagnostic waiting lists for heart conditions, the AI stethoscope’s ability to detect and initiate treatment early could be a turning point.

Unlike traditional procedures with prolonged waiting times for diagnostic tests, the AI stethoscope aims to bridge the gap by providing instant results. For every patient identified in primary care, the NHS stands to save ￡2,500, amounting to significant annual savings for the healthcare system.

Despite the prevalence of heart disease in the UK likely being double the recorded numbers, the AI stethoscope offers hope by addressing gaps in the existing diagnostic process. It aims to provide a swift, reliable diagnosis, closing the detection gap and preventing unnecessary deaths while waiting for confirmatory tests.

Detects three types of heart disease

The deployment of AI stethoscopes in primary care represents a monumental shift in healthcare practices. The Eko stethoscope, with its ability to detect three types of heart disease within 15 seconds, showcases the potential for rapid, effective diagnosis. Although adjustments may be required in terms of design and charging, the positive reception and excitement among healthcare professionals signal a promising future for this transformative technology.

In conclusion, the introduction of AI stethoscopes in primary care brings a new era in healthcare, promising improved diagnostic accuracy, reduced waiting times, and ultimately, enhanced patient outcomes.

Related topics:

Expert’s insight into IoT and AI with professor Alexiei Dingli (www.arciconfraternitadisantamonica.com)

AIBC Forex: Meeting new investment challenges

Implementation strategy for the launch of a new start up (www.arciconfraternitadisantamonica.com)

The post AI stethoscope promises to revolutionize heart disease appeared first on AIBC.

Specialised in respiratory virus

Icosavax, specializing in developing a potential vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus, aligns seamlessly with AstraZeneca’s mission.

The vaccine’s success in the phase 3 trial could position AstraZeneca as a strong contender against established RSV vaccines by GSK and Pfizer, and potentially Moderna. Notably, AstraZeneca’s prior expertise in RSV, through collaboration with Sanofi for an infant protection antibody, adds depth to this strategic acquisition.

Evinova’s pioneering role in clinical trials

Simultaneously, AstraZeneca Plc has unveiled its foray into health technology with the launch of Evinova, a dedicated division aiming to integrate digital solutions and artificial intelligence into clinical trials. This innovative move, announced on Monday, promises to revolutionize clinical trial processes, offering potential cost and time reductions.

Collaborations with Parexel and Fortrea

Evinova has already attracted major players in the drug-testing arena, with Parexel and Fortrea entering collaborations to leverage its digital solutions. AstraZeneca envisions substantial growth in the digital health market, with a focus on research solutions and remote patient monitoring, along with contributions from screening, diagnostics, disease prevention, and digital pharmacies.

By concentrating on the power of digital solutions and AI, Evinova aims to address the longstanding challenges in clinical trials. AstraZeneca emphasizes that, on average, clinical trials take over 7 years to complete, and a staggering 80 percent fail to meet recruitment guidelines.

Evinova’s introduction marks a significant step toward enhancing efficiency and efficacy in the clinical trial landscape, propelling AstraZeneca into the forefront of health technology innovation.

Related topics:

Tailored crypto regulation (www.arciconfraternitadisantamonica.com)

Highlights from AIBC Summit: crypto trends

The post AstraZeneca’s billion-dollar vaccine acquisition follows med-tech advancements appeared first on AIBC.

Government support key for Pharma growth

Dean Li, the President of Merck’s Research Laboratories, has lauded the UK’s wealth of scientific talent and expertise. He envisions the King’s Cross research centre as a hub where Merck’s UK counterpart, MSD, will work closely with academic partners to drive early-stage research critical for developing ground-breaking treatments. However, Li also highlights the presence of certain limitations, cautioning that a broader ecosystem is essential for sustained progress in the field of pharmaceuticals and technology.

Li’s call to action extends to the UK government, urging them to address conflicts within the pharmaceutical industry, notably regarding drug pricing and the challenges of conducting clinical trials within the NHS. He stated the need for the UK to remain competitive on the global stage, as countries like Belgium actively court life sciences investments. The success of Merck’s venture hinges on the government’s commitment to encourage investment driven projects.

Merck’s legacy of advancing medicine through technology

Merck’s investment comes at a time when other pharmaceutical companies express concerns about investing in the UK. AstraZeneca cited a “discouraging tax rate” as a reason for establishing a factory in Ireland instead of the UK, and German drugmaker Bayer reduced its workforce in the UK. The UK government’s ambition to become a life sciences superpower must align with pharmaceutical industry expectations, including considerations related to drug pricing and taxation.

Cutting edge med-tech

The King’s Cross research centre will consolidate scientists currently spread across various locations in the area, effectively doubling the number of researchers working in London. Collaborations with institutions like the Francis Crick Institute and partnerships with London’s esteemed universities are a testament to Merck’s commitment to creating an ecosystem of innovation. MSD’s track record, exemplified by its ground-breaking cancer drug, Keytruda, showcases its capacity to transform healthcare by developing cutting-edge medical technologies.

At the new research facility, scientists will focus on the convergence of neuroscience, inflammation, and immunology, leveraging technologies like 3D printing of cells to unravel the complexities of the brain and develop novel treatments. Dean Li explained the pressing need for advancements in neuroscience, underlining the urgency of investment in this critical field.

Merck’s ￡1 billion investment represents a pivotal moment in the convergence of pharmaceuticals and technology. As the company starts its transformative journey in the UK, it seeks to lead the way in pioneering innovative solutions to address unmet medical needs. It has been made clear that support from the UK government is crucial.

This partnership holds the promise of shaping the future of medical technology and cementing the UK’s place on the global stage of life sciences innovation.

Related topics:

Former advertising executive is Twitter’s new CEO

AIBC Insight: Impact of fintech on Commercial Real Estate

Abu Dhabi Securities Exchange welcomes first listing from UAE

The post Merck’s ￡1 Billion London investment for the future of medical science appeared first on AIBC.

Competitive technology valuation

Abcam CEO Alan Hirzel has vigorously defended the deal, describing the process as robust and competitive. He stated, “This has been a robust process, a competitive process right to the end, and the board has recommended the highest offer.”

Co-founder Milner, who holds a 6.1 percent stake in the company, contends that the offer significantly undervalues Abcam. He also alleges that Danaher’s performance forecasts for Abcam were notably lower than the company’s own guidance, and he accuses the board of not adequately considering other potential buyers.

However, Abcam’s board, in a forthcoming shareholder circular, asserts that the US$24-per-share offer is the “highest and best price” they received after engaging with 30 potential counterparties. These discussions involved 21 companies and 12 financial sponsors. The board further clarified that the closest competing offer had been $22.50, and Danaher had raised its bid twice, starting from an initial offer of $20.50.

Value of technology

Hirzel, who has led a transformation of the company since 2014, emphasized that not only did Danaher offer the highest bid, but they also committed to allowing Abcam to operate independently while developing collaborations in areas such as diagnostics and bioprocessing. Importantly, all bidders, including Danaher, based their valuations on Abcam’s published forecasts, contrary to Milner’s claims of lower estimates.

Abcam, founded in 1998 as a spinout from the University of Cambridge, specializes in creating products for scientific research, such as custom antibodies. Milner, who served as the chief executive until 2014, argues that the company has been mismanaged since his departure. In May, he initiated a campaign to overhaul the board.

The $24-per-share offer, according to the company, represents a 39 percent premium to the undisturbed share price on 16 May, before Milner’s announcement of an extraordinary general meeting, and a 48 percent premium to the volume-weighted average price of $16.21 for the 30 trading days before 16 May.

Dropping AIM listing in favour of Nasdaq

Milner has also raised concerns about whether Abcam management prioritized their own bonuses over the best interests of shareholders. However, Abcam clarified that management compensation remained unchanged due to the deal. Discussions regarding existing management incentive schemes were held after the offer price and other terms had been agreed upon.

Abcam made the strategic move to drop its AIM listing last year in favour of a sole listing on Nasdaq. Milner, on the other hand, believes that a UK listing could be advantageous and has expressed concerns about the future of Abcam’s UK headquarters and jobs. The company has reassured stakeholders that Danaher is committed to maintaining Abcam’s current geographic presence, including its UK headquarters.

In this high-stakes showdown, Abcam is vigorously defending its technology valuation, emphasizing the competitive nature of the negotiations and the compelling offer presented by Danaher. The outcome of this dispute will undoubtedly shape the future direction of Abcam in the rapidly evolving life sciences and technology sectors.

Related topics:

Stop Press: AIBC Europe takes place in Malta between 13 – 17 November?

Binance exits Russian market selling business to newcomer (www.arciconfraternitadisantamonica.com)

Possible IPO for Silicon Valley fintech startup after failed Visa deal (www.arciconfraternitadisantamonica.com)

The post Abcam defends $5.7 billion Danaher acquisition deal appeared first on AIBC.

Messenger RNA technology

Before the pandemic, mRNA technology was an experimental frontier, but it has now been administered to millions worldwide, profoundly impacting the fight against COVID-19. This same revolutionary technology is currently under investigation for applications in other diseases, including cancer.

The Nobel Prize Committee lauded the laureates for their role in accelerating vaccine development at an unprecedented pace during one of the most menacing pandemics that threatened human health in recent history.

Traditional vaccine development traditionally relied on weakened or inactivated pathogens or fragments of infectious agents. In stark contrast, mRNA vaccines, like the Moderna and Pfizer/BioNTech vaccines against COVID-19, adopted an entirely different approach.

Technology’s historical breakthrough

These mRNA vaccines contain genetic instructions for producing a specific viral protein. When introduced into the body, these instructions prompt our cells to manufacture the viral protein in abundance. The immune system recognizes these foreign proteins, initiating a defense response and creating a memory of the virus for future encounters, thereby conferring immunity.

The breakthrough idea behind mRNA technology lies in its ability to rapidly develop vaccines for various threats, provided researchers have the correct genetic instructions. This approach far outpaces traditional vaccine development methods in terms of speed and adaptability.

Moreover, researchers are exploring experimental applications of mRNA technology to teach the body to combat its own cancers. In this approach, scientists analyze a patient’s tumor, identify unique proteins produced by cancer cells, and then design a vaccine to target these specific proteins, which is administered to the patient.

Kariko and Weissman

Professors Katalin Kariko and Drew Weissman were instrumental in achieving the breakthroughs necessary to realize the potential of mRNA vaccines. Their work harnesses the fundamental role of RNA in converting genetic instructions from DNA into the proteins forming the basis of our bodies.

Overcoming challenges associated with the technology, they were able to produce significant quantities of the intended proteins without inducing harmful levels of inflammation, as observed in animal studies. This paved the way for the successful development and application of mRNA vaccine technology in humans.

Today, Professor Katalin Kariko is affiliated with Szeged University in Hungary, while Professor Drew Weissman continues his research at the University of Pennsylvania, leaving an indelible mark on the world of medicine and immunology.

Related topics:

Stop Press: AIBC Europe takes place in Malta between 13 – 17 November?

Binance exits Russian market selling business to newcomer (www.arciconfraternitadisantamonica.com)

Possible IPO for Silicon Valley fintech startup after failed Visa deal (www.arciconfraternitadisantamonica.com)

The post Nobel Prize awarded to pioneers of mRNA vaccine technology appeared first on AIBC.

Diagnostic technology advancement

Attomarker, a venture originating from the University of Exeter, showcased its innovative diagnostic technology at the British Science Festival in Exeter, with CEO Andrew Shaw demonstrating its potential impact on healthcare and data analysis.

The technology has already delivered its first clinical results this year by detecting long Covid through the presence of six antibodies indicating the persistence of the Sars-Cov-2 virus in a patient’s body. Additionally, it is in development for identifying proteins associated with female fertility, food allergies, diabetes, Alzheimer’s and distinguishing bacterial from viral infections to combat antimicrobial resistance.

Currently the technology operates on a laboratory instrument, providing results in seven to 10 minutes. However, Attomarker plans to release a handheld device connected to a mobile phone with a diagnostic cartridge next year.

Securing finance

Andrew Shaw addressed comparisons to Theranos, the fraudulent US blood-testing company, noting the stark contrast in success and funding. Attomarker has managed to raise ￡4.5 million since 2017 and aims to secure an additional ￡3 million by the end of 2023, with plans for a larger Series A funding round in the next two years.

Attomarker’s technology relies on gold nanoparticles on an array of sensor spots, each treated to bind with specific proteins. It can scan for up to 20 biomarkers from a mere 0.01ml blood sample, compared to the 30ml sample required for routine hospital blood tests. When illuminated from below as blood passes over the array, the nanoparticles scatter light in a pattern that indicates the quantity of biomarkers attached to the surface.

Among the numerous applications in development, Shaw highlighted three with significant commercial potential: a device for detecting nine different Alzheimer’s biomarkers, an “infection chip” for distinguishing bacterial and viral infections in cases with vague symptoms, and a hormone-detection tool for fertility and menopause. The mobile device is projected to cost approximately ￡300, with each test array or chip ranging from ￡10 to ￡20. The initial route to market is expected to be private clinics, followed by adoption within the NHS at a later stage.

References to Theranos

Theranos, initially hailed as a healthcare game-changer, ultimately became synonymous with a major corporate fraud. Founded by Elizabeth Holmes in 2003, it promised a revolutionary blood-testing device requiring only a few drops of blood for comprehensive diagnostics.

However, investigations revealed Theranos had deceived investors, patients, and regulators regarding its technology’s capabilities. The Edison machine, meant for these tests, consistently produced inaccurate results, relying heavily on conventional equipment. In 2016, the SEC charged Holmes and Ramesh “Sunny” Balwani with massive fraud, uncovering the extent of the deception.

Theranos collapsed, facing lawsuits, regulatory penalties, and a tarnished reputation. Holmes stood trial for fraud, concluding in 2022 with a mixed verdict. This scandal underscored the need for diligence in healthcare and served as a cautionary tale about unchecked tech ambition.

Innovation in healthcare

It remains to be seen what kind of impact this revolutionary blood test created by UK scientists through Attomarker will have on the healthcare sector. The speed and accuracy of this innovation is key and it will be a significant advancement to diagnose condition s such as like long Covid and Alzheimer’s. It is a significant medical advancement, especially as it identifies multiple biomarkers from a tiny blood sample, surpassing conventional methods.

The technology’s applications, including Alzheimer’s detection and distinguishing bacterial from viral infections, hold immense commercial promise. Attomarker is backed by demonstrated technology and responsible funding, aiming to make a lasting impact on the medical field. This remarkable leap showcases the company’s potential for innovative, reliable and accessible diagnostic solutions in the future of healthcare.

Related topics:

AIBC Forex: Meeting new investment challenges

Implementation strategy for the launch of a new start up (www.arciconfraternitadisantamonica.com)

AIBC Insight: Impact of fintech on Commercial Real Estate

The post Emerging Technology: 10-minute blood test detects long Covid and Alzheimer’s appeared first on AIBC.

Of SpaceX, astronauts and tissue chips

In a recent announcement, NASA disclosed plans for a team of four astronauts to launch to the International Space Station (ISS) by August 25. Their ambitious six-month expedition centres around scientific research aimed at advancing healthcare possibilities on Earth.

The launch, originating from the Kennedy Space Center, features NASA’s SpaceX Crew-7 astronauts, who are poised to execute multiple research projects under the sponsorship of the ISS National Lab.

A notable study involves researchers from the University of California San Francisco. These experts will harness tissue chip technology to uncover the intricate connections between liver regeneration and immune system ageing, with the ultimate aim of discovering innovative strategies for enhancing the liver’s healing process.

Tissue chips are miniature devices with the remarkable ability to mimic human tissue behaviour. Leveraging these chips, scientists can delve into age-related liver concerns and regeneration patterns prevalent among the elderly, all within a microgravity setting.

Over a span of one month, the UC San Francisco research team will investigate the relationship between immune system ageing and healing outcomes, accelerating their findings in comparison to studies conducted on Earth. This acceleration is due to the parallels between physiological changes caused by space conditions and those experienced during the natural aging process.

Of particular interest, many of these changes revert or adjust upon reentry to Earth’s environment, offering a distinct opportunity for a two-way exploration of the ageing process. This investigation holds the potential to unlock insights into reversing immune system ageing, ultimately benefiting life on our cherished home planet.

“Sending these immune chips into space will enable us to simulate the ageing process of the immune system and understand how it affects our body’s ability to repair itself as we grow older,” Sonja Schrepfer, professor of surgery at UCSF and lead of the investigation, said in a statement.

Towards long-term impact

Taking a step back to October, SpaceX embarked on their 5th Commercial Crew mission, dedicating half a year to research conducted in space. Among these efforts was a project focusing on the creation of a protein-based artificial retina and an exploration into the shifts in gut microbes due to the unique space environment.

In the midst of the surging wave of space exploration, concerns related to health and safety are gaining significant attention.

In this context, organizations like the Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine have taken a deep dive into the examination of health factors in space. Their engagement with various groups involves assessing the potential application of these insights to enrich human well-being on Earth.

In the year 2021, TRISH introduced an innovative initiative known as EXPAND (Enhancing eXploration Platforms and Analog Definition). This ingenious research platform compiles data from flights and consolidates it into a comprehensive database. The core objective? To meticulously study astronaut health, refine comprehension, and incubate innovations that can be applied to terrestrial contexts.

Curious about the freshest trends in emerging technology?

Circle November on your calendar, as AIBC Europe is set to unfold at the Mediterranean Maritime Hub (MMH) in Marsa, Malta. Easily accessible through a dedicated ferry service from Valletta, attendees can immerse themselves in rewarding networking sessions, enlightening conferences, and a diverse lineup of exhibitors on the expansive expo floor. Additionally, prominent tech pioneers will convene for confidential C-level meetings in secure berthing zones spanning 100 metres.

While awaiting the event, stay updated on the latest trends in emerging technology. Stay at the forefront with instant updates and dive into engaging feature articles nestled within the pages of the newest edition of BLOCK Magazine.

The post SpaceX astronauts embark on expedition to research reversing immune system ageing appeared first on AIBC.

Revolutionising AI In Healthcare

This pivotal decision, unveiled by Technology Secretary Michelle Donelan, demonstrates a substantial stride towards unleashing AI’s remarkable capacity to reshape the healthcare landscape. The infusion of funds is earmarked for 22 commendable initiatives spanning universities and NHS trusts, spanning the geographical breadth from Edinburgh to Surrey. These endeavours are poised to spark innovation and catalyse a metamorphosis in the quality of patient care.

Offering his perspective, Dr. Antonio Espingardeiro, a seasoned authority in software and robotics and a distinguished member of the IEEE, shares:

“As it becomes more sophisticated, AI can efficiently conduct tasks traditionally undertaken by humans. The potential for the technology within the medical field is huge—it can analyse vast quantities of information and, when coupled with machine learning, search through records and infer patterns or anomalies in data that would otherwise take decades for humans to analyse.

We are just starting to see the beginning of a new era where machine learning could bring substantial value and transform the traditional role of the doctor. The true capabilities of this technology as an aide to the healthcare sector are yet to be fully realised. In the future, we may even be able to solve some of the biggest challenges and issues of our time.”

Among the remarkable initiatives chosen to receive financial support, the spotlight falls on the University College London’s Center for Interventional and Surgical Sciences. Awarded a substantial grant surpassing ￡500,000, the team of researchers embarked on a journey to create a semi-autonomous surgical robotics platform, uniquely tailored to refine the process of brain tumour removal. This ground-breaking innovation holds the potential to elevate surgical success rates, curtail complications, and expedite patients’ road to recovery.

Dr. Espingardeiro continued by highlighting the impact of this progress by stating that, as AI and robotics gain greater prominence, a horizon emerges where healthcare scalability becomes attainable, fostering an environment of more proactive and effective care.

The AI in Healthcare trailblazers

The AI in Healthcare announcement coincided with a week where NHS waiting lists hit an all-time high, aligning with Prime Minister Rishi Sunak’s top priority of reducing waiting lists in 2023.
The announcement coincided with a week where NHS waiting lists hit an all-time high, aligning with Prime Minister Rishi Sunak’s top priority of reducing waiting lists in 2023.
The University of Sheffield has embarked on a ￡463,000 venture, addressing a vital facet of healthcare: chronic nerve pain. Their inventive strategy aims to broaden and enhance the spectrum of treatments available for this ailment, which affects around one in ten adults aged over 30.

On a parallel front, the University of Oxford is propelled by a grant of ￡640,000, aiming to accelerate the progress of researching a fundamental AI model designed for clinical risk prediction. This AI model, by dissecting an individual’s existing health conditions, holds the potential to accurately predict the likelihood of future health issues, thus ushering in a transformative era for early intervention strategies.

Meanwhile, in Edinburgh, Heriot-Watt University secured a notable sum of ￡644,000 to construct a pioneering system that offers real-time feedback to apprentice surgeons honing their skills in laparoscopy procedures, also recognized as keyhole surgeries. This ground-breaking technology aspires to heighten the competency of aspiring surgeons, ultimately elevating the overall quality of healthcare provision.

Concurrently, the University of Surrey, bolstered by a financial backing of ￡456,000, is collaboratively working with radiologists to forge AI technology with the capacity to enhance the analysis of mammograms. By refining and optimising this pivotal diagnostic process, AI could significantly contribute to the earlier detection of cancers.

Commenting on these advancements, Ayesha Iqbal, a distinguished IEEE senior member and engineering mentor at the Advanced Manufacturing Training Centre, expressed:

“The emergence of AI in healthcare has completely reshaped the way we diagnose, treat, and monitor patients.

Applications of AI in healthcare include finding new links between genetic codes, performing robot-assisted surgeries, improving medical imaging methods, automating administrative tasks, personalising treatment options, producing more accurate diagnoses and treatment plans, enhancing preventive care and quality of life, predicting and tracking the spread of infectious diseases, and helping combat epidemics and pandemics.”

In the domain of UK healthcare, AI applications have already demonstrated their potential by enhancing stroke diagnosis, evaluating the risks of heart attacks, and exploring numerous other avenues. In light of these advancements, the injection of ￡13 million is positioned to serve as a dynamic force, propelling healthcare transformation to unprecedented levels.

Health and Social Care Secretary Steve Barclay provided his insights, noting:

“AI can help the NHS improve outcomes for patients, with breakthroughs leading to earlier diagnosis, more effective treatments, and faster recovery. It’s already being used in the NHS in a number of areas, from improving diagnosis and treatment for stroke patients to identifying those most at risk of a heart attack.

This funding is yet another boost to help the UK lead the way in healthcare research. It comes on top of the ￡21 million we recently announced for trusts to roll out the latest AI diagnostic tools and ￡123 million invested in 86 promising tech through our AI in Health and Care Awards.”

Converging AI ethics and efficiency

However, the timing of this announcement coincided with a week where NHS waiting lists reached an unprecedented peak. Prime Minister Rishi Sunak has identified the reduction of waiting lists as one of his top five priorities for 2023, setting a personal commitment to be held accountable for its accomplishment. The potential of technologies like AI is being embraced as a solution to tackle these lengthy waiting lists.

Amidst these developments, the nation is gearing up to host a ground-breaking international summit focused on the safety of AI. This initiative underscores the country’s dedication to cultivating responsible AI advancement.

Set to take place later this year, the AI safety summit will establish a collaborative platform for global stakeholders to address both the potential risks and opportunities presented by AI.

As Europe’s frontrunner in AI and the third-ranking country globally after the USA and China, the UK is strategically positioned to lead these dialogues and advocate for the ethical and conscientious progression of AI technology.

Interested in the latest emerging tech trends?

This November, AIBC Europe is scheduled to take place at the Mediterranean Maritime Hub (MMH) located in Marsa, Malta. With easy access via an exclusive ferry service from Valletta, participants can engage in high-quality networking events, conferences, and a diverse selection of expo floor exhibitors. Additionally, prominent tech brands will partake in confidential C-level meetings within secure berthing areas spanning 100 meters.

In the meantime, keep yourself well-informed about the latest emerging tech trends. Stay ahead of the curve with up-to-the-minute updates from AIBC News, and dive into captivating feature stories within the pages of the newest edition of BLOCK Magazine.

The post Fostering AI progress in healthcare: UK’s ￡13 million research boost appeared first on AIBC.

Closed-loop insulin delivery

One of the most promising breakthroughs is the development of closed-loop insulin delivery systems for diabetes management. These state-of-the-art tech devices combine continuous glucose monitoring with automated insulin administration, effectively mimicking the function of a healthy pancreas. By constantly monitoring blood sugar levels and adjusting insulin dosages in real-time, these systems can help individuals maintain stable glucose levels, reducing the risk of complications and enhancing overall quality of life.

Additionally, the field of bariatric surgery has seen significant advancements in the treatment of obesity. While traditional surgical procedures such as gastric bypass and sleeve gastrectomy have proven effective, emerging technologies are revolutionizing the way obesity is addressed. Intragastric balloons, for instance, offer a non-surgical option by placing an inflatable device within the stomach, inducing feelings of fullness and reducing food intake. Furthermore, technology has allowed minimally invasive procedures such as the endoscopic sleeve to reshape the stomach, promoting weight loss without the need for major surgery.

Novo Nordisk’s Wegovy

Innovations are not limited to devices and surgical procedures alone. The battle against the global rise of diabetes and obesity just got a major boost. Clinical trial results unveiled at a San Diego conference showed promising treatments following Novo Nordisk’s Wegovy drug, leading to weight loss of up to 24 percent. And that’s not all – progress toward effective pill alternatives to Wegovy and Ozempic was also announced, offering hope to the overweight and obese population, provided they can afford these medications.

Medical researchers are also exploring cutting-edge pharmacological approaches, including novel drug therapies that target specific molecular pathways involved in diabetes and obesity. These medications hold promise for managing metabolic disorders by regulating appetite, improving insulin sensitivity, and promoting weight loss.

As these breakthrough technologies continue to advance, it is crucial for regulatory bodies and healthcare providers to collaborate closely to ensure safe and widespread access to these treatments. Informed by rigorous research and clinical trials, these medical marvels are poised to redefine the future of diabetes and obesity management, providing renewed hope for millions of individuals affected by these conditions.

Of course, medications come with health warnings, often hidden within small print on leaflets.

Morgan Stanley forecast

This generation of treatments that mimic the GLP-1 hormone and employ allied mechanisms to combat obesity might yield quick results, but their long-term impact remains uncertain.

First of all, the treatments are bound to remain expensive for years to come. Unlike cardiovascular drugs, which are now affordable, diabetes and obesity medications are still early in their journey. Wegovy, for example, is protected until 2032 in the US. However, investors believe pills will prevail, with Morgan Stanley predicting global obesity drug sales exceeding US $50 billion by 2030.

In addition, the long-term safety of obesity treatments is yet to be established. Although most known side effects are manageable, caution is warranted. The Wegovy leaflet warns of potential thyroid cancer risk, and Pfizer’s shares took a hit after a trial found safety concerns with one of their developing pills. Past history reminds one of the pitfalls, as in the past certain obesity pills promising miraculous results were later banned. However, the approval of Wegovy in the US and Europe may signify a difference this time.

Lastly, shedding pounds does not automatically equate to overall health improvement. While many individuals aim to slim down for aesthetic reasons, the medical purpose of treatment is to reduce susceptibility to illnesses like strokes and cancers.

Eli Lily’s Mounjaro

These warnings shouldn’t discourage us from embracing treatments like Wegovy and upcoming therapies such as Eli Lilly’s Mounjaro. After toiling in the pharmaceutical wilderness for effective solutions, doctors have scientific reasons to seize this new opportunity. However, it’s crucial to tread carefully when the demand for an obesity solution meets an eager pharma industry. Past experiences serve as a reminder that not all miracle pills live up to their promises. Ultimately, maintaining good health requires active participation and lifestyle changes, alongside medical interventions.

As this research and technology enable this exciting frontier to be explored, recognizing a healthy future requires a multifaceted approach beyond relying solely on pharmaceutical and technology breakthroughs.

.Significant impact on Nvidia as Biden restricts export of AI chips (www.arciconfraternitadisantamonica.com)

AIBC Insight: Impact of fintech on Commercial Real Estate

Abu Dhabi Securities Exchange welcomes first listing from UAE

Stop Press ! Find out more about AIBC Asia Summit

The post Breakthrough in medical technologies that will revolutionise diabetes and obesity appeared first on AIBC.